Core Viewpoint - The company is focused on a one-stop platform strategy and antibody strategy, aiming to find relevant target enterprises in the upstream and downstream application fields of antibodies for synergistic development with existing businesses [2] Group 1 - The company is committed to exploring investment opportunities through equity investment funds to identify suitable targets for external development [2] - The company emphasizes the importance of timely information disclosure regarding any significant progress in its investment activities [2] - Investors are encouraged to pay attention to the company's future announcements related to these developments [2]

Core Viewpoint - The company, Uningwei (301166), is focused on its one-stop platform strategy and antibody strategy, aiming to find relevant target companies in the upstream and downstream application fields of antibodies for synergistic development with its existing business [1] Group 1 - The company emphasizes strict compliance with information disclosure regulations and will announce any substantial progress or transactions that meet disclosure standards in a timely manner [1]